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CASE STUDY
40-year-old male patient and 32-year-old female partner, with a history of primary 
infertility of two years duration. The workup revealed idiopathic mild oligoasthenothe-
ratozoospermia, and no apparent female infertility factors. The couple has failed three 
intrauterine insemination (IUI) cycles, planning more IUI cycles but also considering in 
vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI).
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The use of sperm function tests in the 
above scenario is only valid if test results help 
us to guide clinical management and provide be-
nefi t to patients at acceptable costs. Reviewing 
the published literature over the last fi ve years, 
specifi cally concerning the clinical utility of spe-
cialized sperm function tests (SSFTs) for male 
infertility diagnosis, intrauterine insemination 
(IUI), and assisted reproductive technology (ART) 
outcomes, it becomes evident that the current 
research shifted to tests that assess sperm func-
tion at the molecular level. Nevertheless, a few 
studies still explore the use of sperm fertilizing 
ability, such as sperm capacitation and acrosome 
reaction (AR), as potential biomarkers of sperm 
function.
Tests evaluating sperm fertilizing ability
In a 2018 prospective study, Schinfeld and 
colleagues (1) evaluated pregnancy rates according 
to the results of a commercially available assay that 
measures the sperm fertilizing ability by assessing 
capacitation in 91 couples undergoing IUI. The au-
thors found that the likelihood of achieving preg-
nancy by IUI was about 3-fold higher when sperm 
with the so-called ‘high fertilizing potential’ was 
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used for insemination. According to this study, the 
sperm capacitation test could help the clinician to 
decide whether a couple should insist on IUI or bet-
ter move to ART.
In another 2018 study, Xu and colleagues 
(2) examined the utility of the AR test to predict fer-
tilization in 485 couples undergoing conventional 
in vitro fertilization (IVF). The authors found that 
the percentage of sperm exhibiting spontaneous 
AR in neat semen predicted fertilization rates (FR). 
An area under the curve (AUC) of 0.85 (p=0.005) 
for low (FR<30%) or total fertilization failure was 
achieved using a threshold of 9.5%. Thus, accor-
ding to their results, the AR test could help the doc-
tor to decide whether a couple is eligible for con-
ventional IVF or better move to intracytoplasmic 
sperm injection (ICSI).
Tests measuring oxidative stress
Oxidative stress (OS) tests have also been 
explored concerning male infertility diagnosis and 
ART outcomes. In a 2017 study by Agarwal and 
colleagues, the authors measured the oxidation-
-reduction potential (ORP) in 594 infertile men and 
101 fertile controls using a commercially available 
assay, which provides a snapshot of the balance 
between oxidants and reductants in the semen. 
They found that that ORP levels were twice higher 
among infertile men (vs. controls; p<0.001), and 
that the ORP cutoff of 1.42 mV/106 sperm distin-
guished fertile from infertile men with 60.6% sen-
sitivity, 74.3% specificity, and 93.3% positive pre-
dictive value (3).
Using the same assay, a study from Sou-
th Africa involving 51 couples showed that ORP 
results might be useful to predict low fertilization 
(defined as FR<66.7%) as well as live birth rates 
(LBR) by ICSI, with AUCs of 0.81 (p=0.002) and 
0.77 (p=0.0007), respectively (4). The authors also 
showed that ORP results were correlated with sperm 
DNA fragmentation (SDF) values obtained with the 
use of the TUNEL assay (r=0.53; p=0.0001), which 
is not surprising given the well-known association 
between OS and SDF.
Tests evaluating sperm DNA damage
Most current data on the clinical utility of 
SSFTs concern SDF tests. In fact, results of a 2017 
survey study showed that SDF tests are commonly 
requested by fertility specialists, with TUNEL, sperm 
chromatin structure assay (SCSA), sperm chromatin 
dispersion (SCD) test, and Comet assay being the 
four most common assays utilized to measure SDF 
(5). The average reported cost for a SDF test was 
170 US dollars (±123). Among the top 3 indications 
for test requests, i.e., (i) pregnancy failure after IUI, 
IVF, or ICSI, (ii) recurrent miscarriage after IUI, IVF, 
or ICSI, and (iii) recurrent natural pregnancy loss 
(RPL), the case of couples with failed IUI or ART 
ranked first. Interestingly, about two out of three 
responders said that abnormal SDF levels would 
affect their clinical management.
These results are actually not surprising gi-
ven the well-established association between sperm 
DNA damage and risk of infertility (6-11). It has 
also been suggested that SDF negatively affects IUI 
and ART outcomes (12-15). Moreover, the sperm 
genetic defect could be transferred via ART, thus 
potentially affecting the health of resulting offs-
pring (16, 17).
Indeed, big data from a compilation of 28 
studies including 1294 fertile men and 2883 infer-
tile men indicate that SDF testing can be a potent 
tool for male infertility diagnosis, with thresholds 
of 20% having high accuracy (AUC: 0.844; p<0.01) 
to distinguish fertile from subfertile men (18). The-
se results are consistent with those of a landma-
rk study by Ribas-Maynou et al., which showed 
that there exist high correlations (r>0.70; p<0.001) 
and similar thresholds among SCSA (18.9%), SCD 
(22.7%), and TUNEL (20.0%) values concerning 
male infertility diagnosis. In the above study, the 
alkaline Comet assay was also accurate (AUC: 0.93) 
for male infertility diagnosis, but with higher SDF 
thresholds (45.4%) than the three other tests (19).
In our Clinic, SDF results in a consecutive 
cohort of 1639 men - using the SCD test - indicate 
that over 50% of the patients have values of 20% 
and higher. And 25% of our population have SDF 
values of 30% or higher (20). In general, our group 
follows the practice recommendations issued by the 
Society for Translational Medicine in 2017 to re-
quest the SDF test (21). According to these eviden-
ce-based guidelines, the main clinical scenarios for 
testing include (i) Clinical varicocele (in particular, 
grades 2 and 3 varicocele with normal conventio-
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nal semen parameters, and grade 1 varicocele with 
borderline/abnormal conventional semen parame-
ters), (ii) Unexplained infertility/IUI failure/RPL, (iii) 
IVF and/or ICSI failure, and (iv) Borderline abnor-
mal (or normal) semen parameters with risk factor 
(e.g., smoking, obesity, gonadotoxin exposure).
IUI failure seems to be an excellent indica-
tion to recommend the test as patients with high 
SDF would better benefit from ART than IUI. In a 
2007 study involving 387 IUI cycles, LBR of 19% 
and 1.5%, respectively, were achieved when inse-
minations were carried out with semen of men with 
normal and abnormal SDF values, measured by the 
TUNEL assay (6). These results are consistent of tho-
se of a recent systematic review and meta-analysis 
of ten studies and 2839 cycles that showed a strong 
association between SDF and IUI outcomes (15). In 
this study, the relative risk of pregnancy failure by 
IUI was significantly higher in couples whose male 
partners had high SDF (RR 0.34; 95% CI 0.22-0.52; 
I2=1.2%; P<0.001).
Thus, for our patients with IUI failure, like 
the case study under discussion, SDF testing could 
help guide clinical management, albeit the quality 
of the evidence supporting this recommendation is 
not very high (21). For such couples, ART, in par-
ticular, ICSI, would be a better alternative to over-
come SDF-related infertility, possibly due to the 
technical differences between the two methods of 
fertilization (6, 22).
However, despite the better results with 
ART in cases of high SDF, sperm chromatin da-
mage seems to adversely affect both conventio-
nal IVF and ICSI pregnancy outcomes. In a 2017 
review aggregating the data from 70 studies and 
over 17,000 ART cycles, the likelihood of preg-
nancy failure was higher in couples whose male 
partners had high SDF (IVF studies: OR 1.15, 95% 
CI 1.05-1.27, p=0.003; ICSI studies: OR 1.12, 95% 
CI 1.01-1.25, p=0.025). The magnitude of the effect 
varied with the type of SDF assay (TUNEL: OR 1.85; 
95% CI 1.52-2.26, p<0.0001; SCD: OR 1.16, 95% CI 
1.02-1.32, p=0.023; Comet: OR 4.15, 95% CI 3.04-
5.68, p<0.0001; SCSA: OR 1.14, 95% CI  1.04-1.25, 
p=0.004) (14). Notably, the authors showed that the 
clinical utility of the test concerning pregnancy 
prediction increased when female infertility factors 
were excluded (1704 cycles; OR 1.37, 95% CI 1.11-
1.68, p=0.003), thus highlighting the importance of 
SDF to ART outcomes.
Added to the increase in the risk of preg-
nancy failure, SDF also increases the risk of miscar-
riage in pregnancies achieved with the use of both 
conventional IVF and ICSI (16 studies; RR: 2.2; 95% 
CI: 1.54-3.03; p<0.00001) (14, 23). Therefore, SDF 
test results might be used not only to prognosticate 
ART outcomes but also guide clinical management, 
as it has been suggested that ICSI with testicular 
sperm in preference over ejaculated sperm could be 
a valid option to overcome infertility in cases of 
high SDF (21).
A possible explanation for the better ICSI 
outcomes with testicular sperm relates to the ~3-
fold lower SDF in testicular specimens than ejacu-
lated counterparts (24). The susceptibility of sperm 
chromatin to oxidative attack, particularly during 
epididymis transit, is well-established and  might 
explain the low testicular sperm positivity for SDF 
among infertile men (25).
The above findings seem to translate in bet-
ter reproductive outcomes when testicular sperm 
rather than ejaculated sperm are used for ICSI in 
couples whose male partners have confirmed high 
SDF in the semen. In a systematic review of four 
ICSI studies including 507 cycles, the use of testicu-
lar sperm for ICSI improved clinical pregnancy ra-
tes (OR 2.42, 95% CI 1.57-3.73; I2=34%, p<0.0001), 
decreased miscarriage rates (OR 0.28, 95% CI 0.11-
0.68, I2=11%, p=0.005, and increased LBRs (OR 
2.58, 95% CI 1.54-4.35, I2=0%, p=0.0003) (26). 
After that, confirmatory evidence concerning the 
effectiveness of testicular sperm for ICSI has been 
reported by several independent groups (reviewed 
by Lopes & Esteves (27)). Thus, despite the still li-
mited evidence and lack of randomized controlled 
trials, the above data overwhelmingly suggest that 
the SDF test could guide management by selecting 
the couples who might benefit from ICSI with tes-
ticular sperm.
As far as the health of resulting offspring 
is concerned, no study has yet compared ICSI with 
testicular versus ejaculated sperm when both are 
available. However, the published data concerning 
the use of testicular sperm from azoospermic men 
are overall reassuring with regards to the most cri-
tical outcomes (28-30). Moreover, data from the 
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group of Cornell, using comprehensive chromo-
somal evaluation by next-generation sequencing 
(NGS) analysis, indicate that testicular sperm have 
not only lower DNA fragmentation but also lower 
aneuploidy rates than ejaculated sperm (testicular 
sperm: 1.2%; ejaculated sperm: 8.4%; p=0.02) (31). 
Lastly, recent data from our group corroborate the 
safe utilization of testicular sperm. In a 2019 study 
evaluating 363 couples undergoing ICSI, we looked 
at the likelihood of a blastocyst being euploid -by 
NGS- according to the type of sperm used for ICSI 
(32). We found no differences in the probability of a 
metaphase oocyte to turn into a euploid blastocyst 
when ICSI was carried out with the use of testicular 
or ejaculated sperm taken from men with high SDF, 
thus suggesting that testicular sperm is as healthy 
as, if not healthier than, ejaculated sperm.
DISCUSSION
Using SSFTs in clinical practice, the clini-
cian can, first of all, make a more accurate diag-
nosis concerning the male factor contributing to 
infertility. This might help to identify and treat the 
underlying conditions with the aim of improving 
sperm function, possibly impacting positively on 
delivery rates of healthy offspring. Furthermore, 
better patient counseling can be provided concer-
ning treatment outcomes, and lastly, results of tests 
could help us guide clinical management towards 
more personalized and effective ART.
Let us consider the following scenario. An 
IVF Center performs about 1,000 cycles a year with 
an overall clinical pregnancy rate (CPR) of about 
40%. According to the best available evidence from 
14 IVF and ICSI studies involving 2,756 couples, 
the risk of miscarriage is increased in couples with 
high SDF subjected to IVF or ICSI with ejacula-
ted sperm (OR 2.7, 95% CI:1.4-5.1, p=0.003) (13). 
Translating the OR to plain numbers, it means that 
this hypothetical Clinic could lose about 82 preg-
nancies in a year as a result of SDF, thus leading to 
an absolute LBR reduction of about 20%. Naturally, 
fertility clinics cannot afford such a loss, and there-
fore, they should care about SDF testing.
Actually, none of us should ignore the fac-
tors affecting the health of sperm and the resulting 
offspring.  Although ICSI is an extraordinary achie-
vement, evidence accumulated over the last 25 ye-
ars indicates that the health of ICSI offspring might 
be affected, in particular, when the subfertility is 
of male origin (30). The health issues potentially 
related to male subfertility and use of ICSI inclu-
des congenital malformations, childhood cancer, 
psychological and neurological development ab-
normalities, infertility, and cardiometabolic profile 
impairment (reviewed by Esteves et al. (30)).
We advocate the use of SSFTs, in particular 
SDF, to identify and treat the underlying conditions 
associated with abnormal sperm function (20, 33, 
34). For instance, let us consider the case of varico-
cele, whose pathophysiology is linked to OS that is 
a well-known causative factor for SDF. Data from 
21 studies and 1270 infertile men indicate that va-
ricocele repair improves sperm chromatin integrity 
with an average absolute reduction in SDF values of 
about 8% (35). In this review, the reduction in SDF 
after varicocele repair was shown to be translated 
into a higher chance of achieving both natural and 
assisted pregnancies; the mechanism seems to be 
related to the alleviation of OS. Emerging evidence 
also indicates that other interventions, including li-
festyle changes, treatment of genital tract infections, 
and FSH therapy could help to reduce SDF (20, 34).
Therefore, sperm DNA testing can be un-
doubtedly useful in planning ICSI. A high SDF 
test result calls for action, which includes the 
treatment of underlying conditions to impro-
ve both sperm chromatin integrity and fertility 
prospects potentially. When no treatable con-
dition is identified, consideration to ICSI with 
testicular sperm should be given (Figure-1) (24, 
36). However, given the risks associated with 
sperm retrieval (37-40), ICSI with testicular 
sperm should be reserved for men with confir-
med sperm DNA damage or severe oligozoos-
permia/cryptozoospermia (41); this is one of the 
reasons why testing is important.
According to the data of a prospective 
study by our group comparing reproductive ou-
tcomes in 172 oligozoospermic men with high 
SDF treated by ICSI with ejaculated and testicu-
lar sperm, five couples have to be treated by ICSI 
with testicular sperm (versus ICSI with ejaculated 
sperm) to achieve one additional delivery in cou-
ples whose male partners have oligozoospermia 
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and high SDF in semen (42). Whereas this might re-
present more invasive treatments for men, it would 
translate in fewer treatments for women, who are 
generally the ones carrying the burden.
Lastly, it is easy to criticize the SSFTs based 
on the grounds of low predictive values and varia-
ble thresholds (43, 44). However, it is essential to 
understand that infertility is a couple’s problem; it 
is, therefore, evident that a single test from just one 
side will be always limited to provide the full picture 
(45-50). More important is to acknowledge the fact 
that high SDF increases the risk of an adverse repro-
ductive outcome, even with ICSI, and that the risk is 
modulated by female age. The equation relating the 
continuum of SDF values and maternal age makes 
much more sense than fighting about absolute 
thresholds and predictive values, in a scenario where 
pregnancy rates in the best circumstance will rarely 
go beyond 50%. Naturally, sperm DNA testing does 
not replace the adequate male infertility evaluation, 
but they can certainly add independent information 
that could help us to offer better care to our patients. 
So, let us think clinical (and less critical).
FINAL REMARKS
As recently highlighted in an editorial by 
Carrel and Hotaling (51), we as individuals and as 
a medical community providing care to infertili-
ty patients, including urologists, gynecologists, 
and IVF specialists, should ask whether we are 
providing the best care to our patients and the 
child yet to be born, by ignoring the health of 
the sperm. We must also confront the fact that 
ICSI is overused and the male factor is common-
ly overlooked. The financial incentives affecting 
the decision to bypass the male factor infertility 
through ICSI is not without adverse consequen-
ces. The existing data clearly indicate that sperm 
DNA damage is associated with reproductive he-
alth issues in the male and in the embryo. Thus, 
the use of sperm DNA testing is evidence-based 
and should be implemented by ART Clinics and 
doctors not yet using these assays. The primary 
objectives are to improve IUI and ART success, 
but more importantly, to improve the health of 
the father and resulting offspring.
Figure 1 - Proposed algorithm for planning intracytoplasmic sperm injection (ICSI) in cases of high sperm DNA fragmentation (SDF).
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